Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02425891 · OUTCOME

Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) Against Atezolizumab

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) · Source last updated 2022-07-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of participants
Interval / dispersion
Not reported
Time frame
Baseline up to approximately 53 months

What was measured

Percentage of Participants with Anti-Therapeutic Antibodies (ATAs) Against Atezolizumab

Analysis population: The anti-drug antibodies (ADA)-evaluable population is defined as all patients treated with atezolizumab who have at least one post-baseline ADA result.

Groups in this outcome

Atezolizumab Plus Nab-Paclitaxel

Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Atezolizumab Plus Nab-Paclitaxel434

Reported measurements

Baseline Prevalence of ADAs
Values in Percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Atezolizumab Plus Nab-Paclitaxel1.6Not reportedNot reportedNot reportedNot reported
Incidence of Treatment Emergent ADAs
Values in Percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Atezolizumab Plus Nab-Paclitaxel13.1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1.6
    title
    Baseline Prevalence of ADAs
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        13.1
    title
    Incidence of Treatment Emergent ADAs
denoms
  1. counts
    1. group Id
      OG000
      value
      434
    units
    Participants
description
Percentage of Participants with Anti-Therapeutic Antibodies (ATAs) Against Atezolizumab
groups
  1. description
    Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.
    id
    OG000
    title
    Atezolizumab Plus Nab-Paclitaxel
param Type
NUMBER
population Description
The anti-drug antibodies (ADA)-evaluable population is defined as all patients treated with atezolizumab who have at least one post-baseline ADA result.
reporting Status
POSTED
time Frame
Baseline up to approximately 53 months
title
Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) Against Atezolizumab
type
SECONDARY
unit Of Measure
Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice